|
References (abbreviated):
1. Weyand CM, Goronzy JJ. Clinically silent infections in patients
with oligoarthritis: results of a prospective study. Ann Rheum Dis. 1992
Feb;51(2):253-8
2. Fendler C, et al. Frequency of triggering bacteria in patients with
reactive arthritis and undifferentiated oligoarthritis and the relative
importance of the tests used for diagnosis. Ann Rheum Dis. 2001
Apr;60(4):337-43
3. Wucherpfennig KW. Mechanisms for the induction of autoimmunity by
infectious agents. J Clin Invest. 2001 Oct;108(8):1097-104
4. Hemalatha V, et al. Superantigens - Concepts, clinical disease and
therapy. Indian J Med Microbiol 2004;22:204-211
5. Paliard X, et al. Evidence for the effects of a superantigen in
rheumatoid arthritis. Science. 1991 Jul 19;253(5017):325-9
6. Howell MD, et al. Limited T-cell receptor beta-chain heterogeneity
among interleukin 2 receptor-positive synovial T cells suggests a role
for superantigen in rheumatoid arthritis. Proc Natl Acad Sci U S A. 1991
Dec 1;88(23):10921-5
7. Ely PH. The bowel bypass syndrome: a response to bacterial
peptidoglycans. J Am Acad Dermatol. 1980 Jun;2(6):473-87
8. Svartz N. The origin of rheumatoid arthritis. Rheumatology.
1975;6:322-8
9. Shandera WX, Moran A. “Infectious diseases: viral and rickettsial.”
In Tierney LM, McPhee SJ Papadakis MA (eds). Current Medical Diagnosis
and Treatment. 44th edition. New York: Lange; 2005, page 1356-8
10. Simelyte E, et al. Bacterial cell wall-induced arthritis: chemical
composition and tissue distribution of four Lactobacillus strains.
Infect Immun. 2000 Jun;68(6):3535-40
11. Toivanen P. Normal intestinal microbiota in the aetiopathogenesis of
rheumatoid arthritis. Ann Rheum Dis. 2003 Sep;62(9):807-11
12. O'Dwyer ST, et al. A single dose of endotoxin increases intestinal
permeability in healthy humans. Arch Surg. 1988 Dec;123(12):1459-64
13. Shedlofsky SI, et al. Endotoxin depresses hepatic cytochrome
P450-mediated drug metabolism in women. Br J Clin Pharmacol. 1997
Jun;43(6):627-32
14. Kowal C, et al. Cognition and immunity; antibody impairs memory.
Immunity. 2004 Aug;21(2):179-88
15. Fassbender K, et al. The LPS receptor (CD14) links innate immunity
with Alzheimer's disease. FASEB J. 2004 Jan;18(1):203-5
16. Laflamme N, Rivest S. Toll-like receptor 4: the missing link of the
cerebral innate immune response triggered by circulating gram-negative
bacterial cell wall components. FASEB J. 2001 Jan;15(1):155-163
17. Inman RD. Antigens, the gastrointestinal tract, and arthritis. Rheum
Dis Clin North Am. 1991 May;17(2):309-21
18. Abramson SB. Mediators of inflammation, tissue destruction, and
repair: cellular constituents.” In Klippel JH. Primer on the rheumatic
diseases. 11th edition. Atlanta: Arthritis Foundation; 1997, page 39
19. Newkirk MM, et al. Elevated levels of IgM and IgA antibodies to
Proteus mirabilis and IgM antibodies to Escherichia coli are associated
with early rheumatoid factor (RF)-positive rheumatoid arthritis.
Rheumatology (Oxford). 2005 Aug 9; [Epub ahead of print]
20. Van Ghelue M, et al. Autoimmunity to nucleosomes related to viral
infection: a focus on hapten-carrier complex formation. J Autoimmun.
2003 Mar;20(2):171-82
21. Brons RH, et al. Staphylococcal acid phosphatase binds to
endothelial cells via charge interaction; a pathogenic role in Wegener's
granulomatosis? Clin Exp Immunol. 2000 Mar;119(3):566-73
22. Rao T, Richardson B. Environmentally induced autoimmune diseases:
potential mechanisms. Environ Health Perspect. 1999 Oct;107 Suppl
5:737-42
23. Abedi-Valugerdi M, et al. Bacterial lipopolysaccharide both renders
resistant mice susceptible to mercury-induced autoimmunity and
exacerbates such autoimmunity in susceptible mice. Clin Exp Immunol.
2005 Aug;141(2):238-47
24. Campbell DI, et al. Growth faltering in rural Gambian infants is
associated with impaired small intestinal barrier function, leading to
endotoxemia and systemic inflammation. J Nutr. 2003 May;133(5):1332-8
25. Wyatt J, et al. Intestinal permeability and the prediction of
relapse in Crohn's disease. Lancet. 1993 Jun 5;341(8858):1437-9
26. Hijazi Z, et al. Intestinal permeability is increased in bronchial
asthma. Arch Dis Child. 2004 Mar;89(3):227-9
27. Ukabam SO, et al. Small intestinal permeability to sugars in
patients with atopic eczema. Br J Dermatol. 1984 Jun;110(6):649-52
28. Humbert P, et al. Intestinal permeability in patients with
psoriasis. J Dermatol Sci. 1991 Jul;2(4):324-6
29. Fresko I, et al. Intestinal permeability in Behcet's syndrome. Ann
Rheum Dis. 2001 Jan;60(1):65-6
30. Vaile JH, et al. Bowel permeability and CD45RO _expression on
circulating CD20+ B cells in patients with ankylosing spondylitis and
their relatives. J Rheumatol. 1999 Jan;26(1):128-35
31. Di Leo V, et al. Effect of Helicobacter pylori and eradication
therapy on gastrointestinal permeability. Implications for patients with
seronegative spondyloarthritis. J Rheumatol. 2005 Feb;32(2):295-300
32. Picco P, et al. Increased gut permeability in juvenile chronic
arthritides. A multivariate analysis of the diagnostic parameters. Clin
Exp Rheumatol. 2000 Nov-Dec;18(6):773-8
33. Perednia DA, Curosh NA. Lupus-associated protein-losing enteropathy.
Arch Intern Med. 1990 Sep;150(9):1806-10
34. Cooper GS, et al. Associations between plasma DDE levels and
immunologic measures in African-American farmers in North Carolina.
Environ Health Perspect. 2004 Jul;112(10):1080-4.
35. Black CM, et al. Genetic susceptibility to scleroderma-like syndrome
induced by vinyl chloride. Lancet. 1983 Jan 1;1(8314-5):53-5
36. Cooper GS, et al. Occupational risk factors for the development of
systemic lupus erythematosus. J Rheumatol. 2004 Oct;31(10):1928-33
37. Hess EV. Environmental chemicals and autoimmune disease: cause and
effect. Toxicology. 2002 Dec 27;181-182:65-70
38. Rubin RL. Drug-induced lupus. Toxicology. 2005;209(2):135-47
39. von Schmiedeberg S, et al. Polymorphisms of the
xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis
and lupus erythematosus. Adv Exp Med Biol. 1999;455:147-52
40. Crinnion WJ. Results of a decade of naturopathic treatment for
environmental illnesses. J Nat Med 1994;17:21-27
41. Crinnion WJ. Environmental medicine, part one: the human burden of
environmental toxins and their common health effects. Altern Med Rev.
2000 Feb;5(1):52-63
42. Shedlofsky SI, et al. Endotoxin administration to humans inhibits
hepatic cytochrome P450-mediated drug metabolism. J Clin Invest. 1994
Dec;94(6):2209-14
43. Lin HC. Small intestinal bacterial overgrowth: a framework for
understanding irritable bowel syndrome. JAMA. 2004 Aug 18;292(7):852-8
44. Roberts MS, et al. Enterohepatic circulation: physiological,
pharmacokinetic and clinical implications. Clin Pharmacokinet.
2002;41(10):751-90
45. Liska DJ. The detoxification enzyme systems. Altern Med Rev. 1998
Jun;3(3):187-98
46. Lunn PG, Northrop-Clewes CA, Downes RM. Intestinal permeability,
mucosal injury, and growth faltering in Gambian infants. Lancet. 1991
Oct 12;338(8772):907-1
47. Micozzi MS, et al. Bowel function and breast cancer in US women. Am
J Public Health. 1989 Jan;79(1):73-5
48. Petrakis NL, King EB. Cytological abnormalities in nipple aspirates
of breast fluid from women with severe constipation. Lancet. 1981 Nov
28;2(8257):1203-4
49. Ueki A, Otsuka M. Life style risks of Parkinson's disease:
association between decreased water intake and constipation. J Neurol.
2004 Oct;251 Suppl 7:vII18-23
50. Abbott RD, et al. Frequency of bowel movements and the future risk
of Parkinson's disease. Neurology. 2001 Aug 14;57(3):456-62
51. Vella A, Farrugia G. D-lactic acidosis: pathologic consequence of
saprophytism. Mayo Clin Proc. 1998 May;73(5):451-6
52. Sandler RH, et al. Short-term benefit from oral vancomycin treatment
of regressive-onset autism. J Child Neurol. 2000 Jul;15(7):429-35
53. Shaw W, et al. Increased urinary excretion of analogs of Krebs cycle
metabolites and arabinose in two brothers with autistic features. Clin
Chem. 1995 Aug;41(8 Pt 1):1094-104
54. Haan E, et al. Severe illness caused by the products of bacterial
metabolism in a child with a short gut. Eur J Pediatr. 1985
May;144(1):63-5
55. Lennette EH (editor in chief). Manual of Clinical Microbiology.
Fourth Edition. Washington DC; American Society for Microbiology: 1985,
page 269. See also
http://web.indstate.edu/thcme/micro/GI/general/sld038.htm Accessed
10/27/2005
56. Eghbal MA, et al. H2S cytotoxicity mechanism involves reactive
oxygen species formation and mitochondrial depolarisation. Toxicology.
2004 Oct 15;203(1-3):69-76
57. Roediger WE, et al. Reducing sulfur compounds of the colon impair
colonocyte nutrition: implications for ulcerative colitis.
Gastroenterology. 1993 Mar;104(3):802-9
58. Nakoneczna I, et al. The arthritogenic effect of indole, skatole and
other tryptophan metabolites in rabbits. Am J Pathol. 1969
Dec;57(3):523-38
59. Rogers KS, Forbes JC, Nakoneczna I. Arthritogenic properties of
lipophilic, aryl molecules. Proc Soc Exp Biol Med. 1969 Jun;131(2):670-2
60. Person JR, Bernhard JD. Autointoxication revisited. J Am Acad
Dermatol. 1986;15(3):559-63
61. Bastedo WA. Colon irrigations: their administration, therapeutic
applications, and dangers. Journal of the American Medical Association
1932; 98(9): 734-6
62. Marshall HK, Thomson CR. Colon irrigation in the treatment of mental
disease. N Engl J Med 1932; 207 (Sept 8): 454-7
63. Garbat AL, Jacobi HG. Secretion of Bile in Response to Rectal
Installations. Arch Intern Med 1929; 44: 455-462
64. Snyder RG. The value of colonic irrigations in countering
auto-intoxication of intestinal origin. Medical Clinics of North America
1939; May: 781-788
65. Jorizzo JL, et al. Bowel-bypass syndrome without bowel bypass.
Bowel-associated dermatosis-arthritis syndrome. Arch Intern Med. 1983
Mar;143(3):457-61
66. Stein HB, et al. The intestinal bypass: arthritis-dermatitis
syndrome. Arthritis Rheum. 1981 May;24(5):684-90
67. Utsinger PD. Systemic immune complex disease following intestinal
bypass surgery: bypass disease. J Am Acad Dermatol. 1980 Jun;2(6):488-95
68. Kelsall BL, Ravdin JI. Degradation of human IgA by Entamoeba
histolytica. J Infect Dis. 1993 Nov;168(5):1319-22
69. Yokota K, Oguma K. IgA protease produced by Streptococcus sanguis
and antibody production against IgA protease in patients with Behcet's
disease. Microbiol Immunol. 1997;41(12):925-31
70. Kaminishi H, et al. Degradation of humoral host defense by Candida
albicans proteinase. Infect Immun. 1995 Mar;63(3):984-8
71. Douglas LJ. Candida proteinases and candidosis. Crit Rev Biotechnol.
1988;8(2):121-9
72. Miles MR, Olsen L, Rogers A. Recurrent vaginal candidiasis.
Importance of an intestinal reservoir. JAMA. 1977 Oct 24;238(17):1836-7
73. Moraes PS. Recurrent vaginal candidiasis and allergic rhinitis: a
common association. Ann Allergy Asthma Immunol. 1998 Aug;81(2):165-9
74. Neves NA, et al. Association between atopy and recurrent vaginal
candidiasis. Clin Exp Immunol. 2005 Oct;142(1):167-71
75. Shah DT, et al. Effect of gliotoxin on human polymorphonuclear
neutrophils. Infect Dis Obstet Gynecol 1998;6(4):168-75
76. Reinhardt MC. Macromolecular absorption of food antigens in health
and disease. Ann Allergy. 1984 Dec;53(6 Pt 2):597-601
77. Ziambaras T, et al. Regulation of sucrase-isomaltase gene
_expression in human intestinal epithelial cells by inflammatory
cytokines. J Biol Chem. 1996 Jan 12;271(2):1237-42
78. Buret AG. Immunopathology of giardiasis: the role of lymphocytes in
intestinal epithelial injury and malfunction. Mem Inst Oswaldo Cruz.
2005 Mar;100 Suppl 1:185-90
79. Arvanitakis C. Abnormalities of jejunal mucosal enzymes in
ulcerative colitis and Crohn's disease. Digestion. 1979;19(4):259-66
80. Kharazmi A. Mechanisms involved in the evasion of the host defence
by Pseudomonas aeruginosa. Immunol Lett. 1991 Oct;30(2):201-5
81. Over KE, Bucknall RC. Regression of skin changes in a patient with
systemic sclerosis following treatment for bacterial overgrowth with
ciprofloxacin. Br J Rheumatol. 1998 Jun;37(6):696
82. Popa ER, et al. Staphylococcus aureus and Wegener's granulomatosis.
Arthritis Res. 2002;4(2):77-9
83. George J, et al. Infections and Wegener's granulomatosis--a cause
and effect relationship? QJM. 1997 May;90(5):367-73
84. Kobayashi S, Kida I. Reactive arthritis: recent advances and
clinical manifestations. Intern Med. 2005 May;44(5):408-12
85. Tamboli CP, et al. Dysbiosis in inflammatory bowel disease. Gut.
2004 Jan;53(1):1-4
86. Galland L. Intestinal protozoan infection is a common unsuspected
cause of chronic illness. J Advancement Med. 1989;2: 539-552
87. Crook W. The Yeast Connection. Professional Books. Jackson.
Tennessee. 1983
88. D'Acquisto F, et al. Inhibition of Nuclear Factor Kappa B (NF-B)::
An Emerging Theme in Anti-Inflammatory Therapies. Mol Interv. 2002
Feb;2(1):22-35
89. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory
diseases. J Clin Invest. 2001 Jan;107(1):7-11
90. Demircin G, et al. Henoch Schonlein purpura and amebiasis. Acta
Paediatr Jpn. 1998 Oct; 40(5): 489-91
91. Ahmadi K, et al. Antibodies to Klebsiella pneumoniae
lipopolysaccharide in patients with ankylosing spondylitis. Br J
Rheumatol. 1998 Dec;37(12):1330-3
92. Rashid T, et al. Proteus IgG antibodies and C-reactive protein in
English, Norwegian and Spanish patients with rheumatoid arthritis. Clin
Rheumatol 1999;18(3):190-5
93. Wilson C, et al. Cytotoxicity responses to Peptide antigens in
rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2003
May;30(5):972-8
94. Hughes LE, et al. Antibody responses to Acinetobacter spp. and
Pseudomonas aeruginosa in multiple sclerosis: prospects for diagnosis
using the myelin-acinetobacter-neurofilament antibody index. Clin Diagn
Lab Immunol. 2001 Nov;8(6):1181-8
95. Melby KK, et al. Helicobacter pylori--a trigger of reactive
arthritis? Infection. 1999;27(4-5):252-5
96. Attributed to Galland L. “Fire in the belly: update on gut
fermentation.” Presented to Great Lakes Association of Clinical
Medicine, circa 1996. Also, personal email from Leo Galland dated
October 28, 2005: "I have used the concept of 4 types of dysbiosis
(putrefaction, fermentation, depletion and immune activation forms) in
several presentations and in one written document."
97. Saltzman JR, Russell RM. Nutritional consequences of intestinal
bacterial overgrowth. Compr Ther. 1994;20(9):523-30
98. Lichtman SN, et al. Reactivation of arthritis induced by small bowel
bacterial overgrowth in rats: role of cytokines, bacteria, and bacterial
polymers. Infect Immun. 1995 Jun;63(6):2295-301
99. Pimentel M, et al. A link between irritable bowel syndrome and
fibromyalgia may be related to findings on lactulose breath testing. Ann
Rheum Dis. 2004 Apr;63(4):450-2
100. Bundgaard H, et al. Endotoxemia stimulates skeletal muscle Na+-K+-ATPase
and raises blood lactate under aerobic conditions in humans. Am J
Physiol Heart Circ Physiol. 2003 Mar;284(3):H1028-34
101. Apperloo-Renkema HZ, et al. Host-microflora interaction in systemic
lupus erythematosus (SLE): colonization resistance of the indigenous
bacteria of the intestinal tract. Epidemiol Infect. 1994
Apr;112(2):367-73
102. Pisetsky DS. Antibody responses to DNA in normal immunity and
aberrant immunity. Clin Diagn Lab Immunol. 1998 Jan;5(1):1-6
103. Zaidel O, Lin HC. Uninvited guests: the impact of small intestinal
bacterial overgrowth on nutrition. Practical Gastroenterology 2003;
27(7):27-34
104. Fairris GM, et al. A dermatosis associated with bacterial
overgrowth in jejunal diverticula. Br J Dermatol. 1985 Jun;112(6):709-13
105. Shah DT, et al. Effect of gliotoxin on human polymorphonuclear
neutrophils. Infect Dis Obstet Gynecol. 1998;6(4):168-75
106. Shah DT, et al. In situ mycotoxin production by Candida albicans in
women with vaginitis. Gynecol Obstet Invest. 1995;39(1):67-9
107. Doby T. Monilial esophagitis and colitis. J Maine Med Assoc. 1971
May;62(5):109-14
108. Schreiber J, Struben C, Rosahl W, Amthor M. Hypersensitivity
alveolitis induced by endogenous candida species. Eur J Med Res. 2000
Mar 27;5(3):126
109. Ramirez De Knott HM, et al. Cutaneous hypersensitivity to Candida
albicans in idiopathic vulvodynia. Contact Dermatitis. 2005
Oct;53(4):214-8
110. Brook I. Bacteriology of chronic maxillary sinusitis in adults. Ann
Otol Rhinol Laryngol. 1989 Jun;98(6):426-8
111. Jiang RS, Hsu CY, Leu JF. Bacteriology of ethmoid sinus in chronic
sinusitis. Am J Rhinol. 1997 Mar-Apr;11(2):133-7
112. Ponikau JU, et al. The diagnosis and incidence of allergic fungal
sinusitis. Mayo Clin Proc. 1999 Sep;74(9):877-84
113. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused
by oral infection. Clin Microbiol Rev. 2000 Oct;13(4):547-58
114. Amar S, Han X. The impact of periodontal infection on systemic
diseases. Med Sci Monit. 2003 Dec;9(12):RA291-9
115. Erlacher L, et al. Reactive arthritis: urogenital swab culture is
the only useful diagnostic method for the detection of the arthritogenic
infection in extra-articularly asymptomatic patients with
undifferentiated oligoarthritis. Br J Rheumatol. 1995 Sep;34(9):838-42
116. Delyle LG, et al. Chronic destructive oligoarthritis associated
with Propionibacterium acnes in a female patient with acne vulgaris:
septic-reactive arthritis? Arthritis Rheum. 2000 Dec;43(12):2843-7
117. Schaeverbeke T, et al. Propionibacterium acnes isolated from
synovial tissue and fluid in a patient with oligoarthritis associated
with acne and pustulosis. Arthritis Rheum. 1998 Oct;41(10):1889-93
118. Diri E, et al. Papulopustular skin lesions are seen more frequently
in patients with Behcet's syndrome who have arthritis: a controlled and
masked study. Ann Rheum Dis. 2001 Nov;60(11):1074-6
119. Campbell AW, et al. Neural autoantibodies and neurophysiologic
abnormalities in patients exposed to molds in water-damaged buildings.
Arch Environ Health. 2003 Aug;58(8):464-74
120. Gray MR, et al. Mixed mold mycotoxicosis: immunological changes in
humans following exposure in water-damaged buildings. Arch Environ
Health. 2003 Jul;58(7):410-20
121. O'Gorman MA, et al. Prevalence and characteristics of Blastocystis
hominis infection in children. Clin Pediatr (Phila) 1993 Feb;32(2):91-6
122. Telalbasic S, et al. Blastocystis hominis may be a potential cause
of intestinal disease. Scand J Infect Dis 1991;23(3):389-90
123. Sheehan DJ, et al. Association of Blastocystis hominis with signs
and symptoms of human disease. J Clin Microbiol. 1986;24(4):548-50
124. Diaczok BJ, Rival J. Diarrhea due to Blastocystis hominis: an old
organism revisited. South Med J 1987 Jul;80(7):931-2
125. Russo AR, et al. Presumptive evidence for Blastocystis hominis as a
cause of colitis. Arch Intern Med. 1988 May;148(5):1064
126. Burnstein SL, Liakos S. Parasitic rheumatism presenting as
rheumatoid arthritis. J Rheumatol. 1983 Jun;10(3):514-5
127. Huston CD. Parasite and host contributions to the pathogenesis of
amebic colitis. Trends Parasitol. 2004 Jan; 20(1): 23-6
128. Demircin G, et al. Henoch Schonlein purpura and amebiasis. Acta
Paediatr Jpn. 1998 Oct; 40(5): 489-91
129. Galland L, Lee M. #170 High frequency of giardiasis in patients
with chronic digestive complaints. Am J Gastroenterol 1989;84:1181
130. Hasegawa T, et al. Effects of bacterial endotoxin on drug
pharmacokinetics. Nagoya J Med Sci 1999 May;62(1-2):11-28
131. Hahn RG, et al. Evaluation of poststreptococcal illness. Am Fam
Physician. 2005 May 15;71(10):1949-54
132. Chikkamuniyappa S. Streptococcal toxic shock syndrome and sepsis
manifesting in a patient with chronic rheumatoid arthritis. Dermatol
Online J. 2004 Jul 15;10(1):7
133. Lynn E. Hancock and Michael S. Gilmore. Department of Microbiology
and Immunology, University of Oklahoma Health Sciences Center.
Pathogenicity of Enterococci published in "Gram-Positive Pathogens"
edited by Fischetti V et al. http://w3.ouhsc.edu/enterococcus/lynn_revirew.asp
134. Shandera WX, Moran A. “Infectious diseases: viral and rickettsial.”
In Tierney LM, McPhee SJ Papadakis MA (eds). Current Medical Diagnosis
and Treatment. 44th edition. New York: Lange; 2005, page 1356-8
135. Watanabe H, et al. Enterocolitis caused by methicillin-resistant
Staphylococcus aureus: molecular characterization of respiratory and
digestive tract isolates. Microbiol Immunol. 2001;45(9):629-34
136. Farraye FA, et al. Segmental colitis associated with Aeromonas
hydrophila. Am J Gastroenterol. 1989 Apr;84(4):436-8
137. Cuffari C, Oligny L, Seidman EG. Dientamoeba fragilis masquerading
as allergic colitis. J Pediatr Gastroenterol Nutr. 1998 Jan;26(1):16-20
138. Trollmo C, et al. Fasting enhances mucosal antigen specific B cell
responses in rheumatoid arthritis. Ann Rheum Dis. 1997 Feb;56(2):130-4
139. Ramakrishnan T, Stokes P. Beneficial effects of fasting and low
carbohydrate diet in D-lactic acidosis associated with short-bowel
syndrome. JPEN J Parenter Enteral Nutr. 1985 May-Jun;9(3):361-3
140. Gottschall E. Breaking the Vicious Cycle: Intestinal Health Through
Diet. Kirkton Press; Rev edition (August 1, 1994)
141. Muller H, et al. Fasting followed by vegetarian diet in patients
with rheumatoid arthritis: a systematic review. Scand J Rheumatol.
2001;30(1):1-10
142. Ferri C, et al. Low-antigen-content diet in the treatment of
patients with mixed cryoglobulinemia. Am J Med. 1989 Nov;87(5):519-24
143. Pietrogrande M, et al. Dietetic treatment of essential mixed
cryoglobulinemia. Ric Clin Lab. 1986 Apr-Jun;16(2):413-6
144. Force M, Sparks WS, Ronzio RA. Inhibition of enteric parasites by
emulsified oil of oregano in vivo. Phytother Res. 2000 May;14(3):213-4
145. Stiles JC, Sparks W, Ronzio RA. The inhibition of Candida albicans
by oregano. J Applied Nutr 1995;47:96–102
146. Berberine. Altern Med Rev. 2000 Apr;5(2):175-7
147. Dien TK, de Vries PJ, Khanh NX, Koopmans R, Binh LN, Duc DD, Kager
PA, van Boxtel CJ. Effect of food intake on pharmacokinetics of oral
artemisinin in healthy Vietnamese subjects. Antimicrob Agents Chemother.
1997 May;41(5):1069-72
148. Giao PT, et al. Artemisinin for treatment of uncomplicated
falciparum malaria: is there a place for monotherapy? Am J Trop Med Hyg.
2001 Dec;65(6):690-5
149. Schempp CM, et al. Antibacterial activity of hyperforin from St
John's wort, against multiresistant Staphylococcus aureus and
gram-positive bacteria. Lancet. 1999 Jun 19;353(9170):2129
150. Gibbons S, et al. The genus Hypericum--a valuable resource of
anti-Staphylococcal leads. Fitoterapia. 2002 Jul;73(4):300-4
151. Reichling J, et al. A current review of the antimicrobial activity
of Hypericum perforatum L. Pharmacopsychiatry. 2001 Jul;34 Suppl
1:S116-8
152. El Baz MA, et al. Clinical and parasitological studies on the
efficacy of Mirazid in treatment of schistosomiasis haematobium in
Tatoon, Etsa Center, El Fayoum Governorate. J Egypt Soc Parasitol. 2003
Dec;33(3):761-76
153. Abo-Madyan AA, et al. Efficacy of Myrrh in the treatment of
schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia
Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol. 2004
Aug;34(2):423-46
154. Yarnell E. Botanical medicines for the urinary tract. World J Urol.
2002 Nov;20(5):285-93
155. Wang L, Del Priore LV. Bull's-eye maculopathy secondary to herbal
toxicity from uva ursi. Am J Ophthalmol. 2004 Jun;137(6):1135-7
156. Lynch DM. Cranberry for prevention of urinary tract infections. Am
Fam Physician. 2004 Dec 1;70(11):2175-7
157. Fujita M, et al. Remarkable synergies between baicalein and
tetracycline, and baicalein and beta-lactams against methicillin-resistant
Staphylococcus aureus. Microbiol Immunol. 2005;49(4):391-6
158. Fabio A, et al. Inhibitory activity of spices and essential oils on
psychrotrophic bacteria. New Microbiol. 2003 Jan;26(1):115-20
159. Chami N, et al. Antifungal treatment with carvacrol and eugenol of
oral candidiasis in immunosuppressed rats. Braz J Infect Dis. 2004
Jun;8(3):217-26
160. Elgayyar M, et al. Antimicrobial activity of essential oils from
plants against selected pathogenic and saprophytic microorganisms. J
Food Prot. 2001 Jul;64(7):1019-24
161. Simpson D. Buchu--South Africa's amazing herbal remedy. Scott Med J
1998 Dec;43(6):189-91
162. Jirovetz L, et al. Composition, quality control, and antimicrobial
activity of the essential oil of long-time stored dill (Anethum
graveolens L.) seeds from Bulgaria. J Agric Food Chem. 2003 Jun
18;51(13):3854-7
163. Murnigsih T, et al. Evaluation of the inhibitory activities of the
extracts of Indonesian traditional medicinal plants against Plasmodium
falciparum and Babesia gibsoni. J Vet Med Sci. 2005 Aug;67(8):829-31
164. Wright CW, et al. Use of microdilution to assess in vitro
antiamoebic activities of Brucea javanica fruits, Simarouba amara stem,
and a number of quassinoids. Antimicrob Agents Chemother. 1988
Nov;32(11):1725-9
165. Sawangjaroen N, Sawangjaroen K. The effects of extracts from
anti-diarrheic Thai medicinal plants on the in vitro growth of the
intestinal protozoa parasite: Blastocystis hominis. J Ethnopharmacol.
2005 Apr 8;98(1-2):67-72
166. Yang LQ, et al. In vitro response of Blastocystis hominis against
traditional Chinese medicine. J Ethnopharmacol. 1996 Dec;55(1):35-42
167. Rani P, Khullar N. Antimicrobial evaluation of some medicinal
plants for their anti-enteric potential against multi-drug resistant
Salmonella typhi. Phytother Res. 2004 Aug;18(8):670-3
168. Liebow C, Rothman SS. Enteropancreatic Circulation of Digestive
Enzymes. Science 1975; 189(4201): 472-474
169. Vasquez A. Reducing pain and inflammation naturally - Part 3:
Improving overall health while safely and effectively treating
musculoskeletal pain. Nutritional Perspectives 2005; 28: 34-38, 40-42
http://optimalhealthresearch.com/part3
170. Galebskaya LV, et al. Human complement system state after wobenzyme
intake. VESTNIK MOSKOVSKOGO UNIVERSITETA. KHIMIYA. 2000. Vol. 41, No. 6.
Supplement. Pages 148-149
171. Edwards JC, Cambridge G. Rheumatoid arthritis: the predictable
effect of small immune complexes in which antibody is also antigen. Br J
Rheumatol. 1998 Feb;37(2):126-30
172. Jancar S, Sanchez Crespo M. Immune complex-mediated tissue injury:
a multistep paradigm. Trends Immunol. 2005 Jan;26(1):48-55
173. Zavadova E, et al. Stimulation of reactive oxygen species
production and cytotoxicity in human neutrophils in vitro and after oral
administration of a polyenzyme preparation. Cancer Biother. 1995
Summer;10(2):147-52
174. “The enzymes were shown to inhibit the biofilm formation. When
applilied to the formed associations, the enzymes potentiated the effect
of antibiotics on the bacteria located in them.” Tets VV, Knorring GIu,
Artemenko NK, Zaslavskaia NV, Artemenko KL. [Impact of exogenic
proteolytic enzymes on bacteria][Article in Russian] Antibiot Khimioter.
2004;49(12):9-13
175. Isolauri E, et al. Probiotics: effects on immunity. Am J Clin Nutr.
2001 Feb;73(2 Suppl):444S-450S
176. Liu Q, Duan ZP, et al. Synbiotic modulation of gut flora: effect on
minimal hepatic encephalopathy in patients with cirrhosis. Hepatology.
2004 May;39(5):1441-9
177. Simenhoff ML, et al. Biomodulation of the toxic and nutritional
effects of small bowel bacterial overgrowth in end-stage kidney disease
using freeze-dried Lactobacillus acidophilus. Miner Electrolyte Metab.
1996;22(1-3):92-6
178. Seaman DR. The diet-induced pro-inflammatory state: a cause of
chronic pain and other degenerative diseases? J Manipulative Physiol
Ther. 2002 Mar-Apr;25(3):168-79. See also Vasquez A. Chiropractic and
Naturopathic Medicine for the Promotion of Wellness and Alleviation of
Pain and Inflammation.
179. Miller AL. Therapeutic considerations of L-glutamine: a review of
the literature. Altern Med Rev. 1999 Aug;4(4):239-48
180. Beck MA. Nutritionally induced oxidative stress: effect on viral
disease. Am J Clin Nutr. 2000 Jun;71(6 Suppl):1676S-81S
181. Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D
(cholecalciferol): a paradigm shift with implications for all healthcare
providers. Altern Ther Health Med. 2004 Sep-Oct;10(5):28-36
182. Mero A, et al. IGF-I, IgA, and IgG responses to bovine colostrum
supplementation during training. J Appl Physiol. 2002 Aug;93(2):732-9
183. Stephan W, et al. Antibodies from colostrum in oral immunotherapy.
J Clin Chem Clin Biochem. 1990 Jan;28(1):19-23
184. Pandolfi F, et al. T-dependent immunity in aged humans. II.
Clinical and immunological evaluation after three months of
administering a thymic extract. Thymus. 1983 Apr;5(3-4):235-40
185. Lavastida MT, et al. Thymosin administration in autoimmune
disorders. Thymus. 1981 Feb;2(4-5):287-95
186. Thrower PA, et al. Thymopoietin in rheumatoid arthritis. Rheumatol
Rehabil. 1982 May;21(2):72-7
187. Malaise MG, et al. Treatment of active rheumatoid arthritis with
slow intravenous injections of thymopentin. A double-blind
placebo-controlled randomised study. Lancet. 1985 Apr 13;1(8433):832-6
188. Manti F, et al. Effects of an immunomodulating agent on peripheral
blood lymphocytes and subgingival microflora in ligature-induced
periodontitis. Infect Immun. 1984 Jul;45(1):172-9
189. McPhaul JJ Jr. IgA-associated glomerulonephritis. Annu Rev Med.
1977;28:37-42
190. Rai A, et al. Henoch-Schonlein purpura nephritis. J Am Soc Nephrol.
1999 Dec;10(12):2637-44
191. Voskuyl AE, et al. Diagnostic strategy for the assessment of
rheumatoid vasculitis. Ann Rheum Dis. 2003 May;62(5):407-13
192. Sikander FF, et al. Cryoglobulin studies in systemic lupus
erythematosus. J Postgrad Med 1989;35:139-43
193. Pourmand N, et al. Ro/SSA and La/SSB specific IgA autoantibodies in
serum of patients with Sjogren's syndrome and systemic lupus
erythematosus. Ann Rheum Dis. 1999 Oct;58(10):623-9
194. Jonsson T, Valdimarsson H. What about IgA rheumatoid factor in
rheumatoid arthritis? Ann Rheum Dis. 1998 Jan;57(1):63-4
195. Russell MW, et al. Immunoglobulin A-mediated hepatobiliary
transport constitutes a natural pathway for disposing of bacterial
antigens. Infect Immun. 1983 Dec;42(3):1041-8
196. Russell MW, et al. Preferential transport of IgA and IgA-immune
complexes to bile compared with other external secretions. Mol Immunol.
1982 May;19(5):677-82
197. Phillips JO, et al. Role of hepatocytes in the uptake of IgA and
IgA-containing immune complexes in mice. Mol Immunol. 1988
Sep;25(9):873-9
198. Brown TA, et al. IgA-mediated elimination of antigens by the
hepatobiliary route. Fed Proc. 1983 Dec;42(15):3218-21
199. Harmatz PR, et al. The effect of bile duct obstruction on the
clearance of circulating IgA immune complexes. Hepatology. 1984
Jan-Feb;4(1):96-100
200. Lemaitre-Coelho I, et al. High levels of secretory IgA and free
secretory component in the serum of rats with bile duct obstruction. J
Exp Med. 1978 Mar 1;147(3):934-9
201. Sung JJ, et al. Biliary IgA secretion in obstructive jaundice: the
effects of endoscopic drainage. Gastrointest Endosc. 1995
Nov;42(5):439-44
202. Gonzalez NJ, Isaacs LL. Evaluation of pancreatic proteolytic enzyme
treatment of adenocarcinoma of the pancreas, with nutrition and
detoxification support. Nutr Cancer. 1999;33(2):117-24
203. Braun N, et al. Immunoadsorption onto protein A induces remission
in severe systemic lupus erythematosus. Nephrol Dial Transplant. 2000
Sep;15(9):1367-72
204. Santos-Ocampo AS, et al. Alveolar hemorrhage in systemic lupus
erythematosus: presentation and management. Chest. 2000
Oct;118(4):1083-90
205. Choi BG, Yoo WH. Successful treatment of pure red cell aplasia with
plasmapheresis in a patient with systemic lupus erythematosus. Yonsei
Med J. 2002 Apr;43(2):274-8
206. Yamahara J, et al. Cholagogic effect of ginger and its active
constituents. J Ethnopharmacol. 1985 May;13(2):217-25
207. Rasyid A, Lelo A. The effect of curcumin and placebo on human
gall-bladder function: an ultrasound study. Aliment Pharmacol Ther. 1999
Feb;13(2):245-9
208. Saraswat B, et al. Anticholestatic effect of picroliv, active
hepatoprotective principle of Picrorhiza kurrooa, against carbon
tetrachloride induced cholestasis. Indian J Exp Biol. 1993
Apr;31(4):316-8
209. Crocenzi FA, et al. Preventive effect of silymarin against
taurolithocholate-induced cholestasis in the rat. Biochem Pharmacol.
2003 Jul 15;66(2):355-64
210. Shukla B, et al. Choleretic effect of andrographolide in rats and
guinea pigs. Planta Med. 1992 Apr;58(2):146-9
211. Chandan BK, et al. Boerhaavia diffusa: a study of its
hepatoprotective activity. J Ethnopharmacol. 1991 Mar;31(3):299-307
212. Ayaslioglu E, et al. Evidence of chronic Chlamydia pneumoniae
infection in patients with Behcet's disease. Scand J Infect Dis.
2004;36(6-7):428-30
213. Hatemi G, et al. The pustular skin lesions in Behcet's syndrome are
not sterile. Ann Rheum Dis. 2004 Nov;63(11):1450-2
214. Vasquez A. Reducing Pain and Inflammation Naturally. Part 1: New
Insights into Fatty Acid Biochemistry and the Influence of Diet.
Nutritional Perspectives 2004; October: 5, 7-10, 12, 14
215. Vasquez A. Reducing Pain and Inflammation Naturally. Part 2: New
Insights into Fatty Acid Supplementation and Its Effect on Eicosanoid
Production and Genetic _Expression. Nutritional Perspectives 2005;
January: 5-16
216. Vasquez A. Reducing pain and inflammation naturally - Part 3:
Improving overall health while safely and effectively treating
musculoskeletal pain. Nutritional Perspectives 2005; 28: 34-38, 40-42
217. Vasquez A. Reducing pain and inflammation naturally - Part 4:
Nutritional and Botanical Inhibition of NF-kappaB, the Major
Intracellular Amplifier of the Inflammatory Cascade. A Practical
Clinical Strategy Exemplifying Anti-Inflammatory Nutrigenomics.
Nutritional Perspectives 2005;July: 5-12
218. Vasquez A. Reducing pain and inflammation naturally - Part 5:
Improving neuromusculoskeletal health by optimizing immune function and
reducing allergic reactions. Nutritional Perspectives 2005;August:
27-35, 40
219. Vasquez A. Integrative Rheumatology. Volume One: Autoimmune
Disorders.
www.OptimalHealthResearch.com
|
